HHLR ADVISORS, LTD.
13F Holdings and Portfolio Analysis
Zhang Lei 2022 Q4 13F holdings, quarterly changes, portfolio value trend and position weight distribution.
HHLR ADVISORS, LTD. Overview
HHLR ADVISORS, LTD. held 67 stocks in 2022 Q4, with total market value around $4.74B.
HHLR ADVISORS, LTD.'s top five holdings in 2022 Q4: BeOne Medicines AG(ONC) 25.41%, JD.com, Inc.(JD) 7.85%, KE Holdings Inc.(BEKE) 6.20%, Alibaba Group Holding Limited(BABA) 5.81%, Vipshop Holdings Limited(VIPS) 5.47%.
- Portfolio Value
- $4.74B
- Current Holdings
- 67 stocks
- New / Increased
- 13 / 9
- Reduced / Exited
- 24 / 7
Current Holdings
| 1 | BeOne Medicines AGONC | 1.20 | 25.41% | 5.47 - | $219.94 | $316.42 +43.87% | $136.90 | 0.00 | 4.25 | +$0.98B+131.14% | Held |
| 2 | JD.com, Inc.JD | 0.37 | 7.85% | 6.62 +4.08% | $56.13 | $33.07 -41.08% | $58.61 | +0.26 | 4.25 | -$0.17B-43.57% | Increased |
| 3 | KE Holdings Inc.BEKE | 0.29 | 6.20% | 21.05 +89.29% | $13.96 | $18.29 +31.02% | $18.66 | +9.93 | 2.50 | -$0.01B-2.01% | Increased |
| 4 | Alibaba Group Holding LimitedBABA | 0.28 | 5.81% | 3.12 +39.53% | $88.09 | $125.39 +42.34% | $102.69 | +0.88 | 0.75 | +$0.07B+22.11% | Increased |
| 5 | Vipshop Holdings LimitedVIPS | 0.26 | 5.47% | 18.99 -5.73% | $13.64 | $14.22 +4.25% | $6.43 | -1.15 | 2.00 | +$0.15B+121.29% | Reduced |
| 6 | Legend Biotech CorporationLEGN | 0.26 | 5.41% | 5.14 - | $49.92 | $31.96 -35.98% | $70.17 | 0.00 | 2.75 | -$0.20B-54.45% | Held |
| 7 | Freeport-McMoRan Inc.FCX | 0.24 | 5.03% | 6.27 | $38.00 | $41.18 +8.37% | $38.00 | +6.27 | 0.25 | +$0.02B+8.37% | New |
| 8 | PDD HOLDINGS INC COMMON STOCKPDD | 0.24 | 5.00% | 2.90 +44.33% | $81.55 | $88.14 +8.09% | $68.03 | +0.89 | 0.75 | +$0.06B+29.57% | Increased |
| 9 | Salesforce, Inc.CRM | 0.23 | 4.85% | 1.73 -28.45% | $132.59 | $210.90 +59.06% | $207.81 | -0.69 | 3.00 | +$0.01B+1.48% | Reduced |
| 10 | DoorDash, Inc.DASH | 0.22 | 4.64% | 4.50 -3.98% | $48.82 | $154.61 +216.69% | $50.74 | -0.19 | 2.25 | +$0.47B+204.68% | Reduced |
| 11 | On Holding AGONON | 0.09 | 1.98% | 5.47 - | $17.16 | $41.82 +143.71% | $30.13 | 0.00 | 1.50 | +$0.06B+38.80% | Held |
| 12 | Cytek Biosciences, Inc.CTKB | 0.09 | 1.87% | 8.68 -0.83% | $10.21 | $3.95 -61.31% | $21.41 | -0.07 | 1.50 | -$0.15B-81.55% | Reduced |
| 13 | DAQO NEW ENERGY CORPDQ | 0.08 | 1.71% | 2.10 - | $38.61 | - | $68.07 | 0.00 | 1.00 | -$0.06B-43.28% | Held |
| 14 | Mondelez International, Inc.MDLZ | 0.07 | 1.51% | 1.07 -42.50% | $66.65 | $62.41 -6.36% | $40.03 | -0.79 | 4.25 | +$0.02B+55.91% | Reduced |
| 15 | iQIYI, Inc.IQ | 0.06 | 1.36% | 12.16 -21.09% | $5.30 | $2.03 -61.70% | $18.04 | -3.25 | 4.25 | -$0.19B-88.75% | Reduced |
| 16 | Yatsen Holding LimitedYSG | 0.05 | 1.08% | 34.94 - | $1.46 | $8.42 +476.71% | $2.24 | 0.00 | 2.25 | +$0.22B+275.54% | Held |
| 17 | Coupang, Inc.CPNG | 0.05 | 1.05% | 3.38 - | $14.71 | $16.68 +13.39% | $18.62 | 0.00 | 1.50 | -$0.01B-10.44% | Held |
| 18 | ENFUSION INCENFN | 0.05 | 1.02% | 4.98 - | $9.67 | - | $20.94 | 0.00 | 1.25 | -$0.06B-53.82% | Held |
| 19 | MICROSOFT CORP COMMSFT | 0.04 | 0.88% | 0.17 +15.76% | $239.82 | $460.25 +91.91% | $239.34 | +0.02 | 0.75 | +$0.04B+92.30% | Increased |
| 20 | BridgeBio Pharma, Inc.BBIO | 0.04 | 0.83% | 5.19 -3.26% | $7.62 | $54.92 +620.73% | $20.26 | -0.17 | 3.75 | +$0.18B+171.13% | Reduced |
| 21 | Kiniksa Pharmaceuticals International, plcKNSA | 0.04 | 0.83% | 2.62 -10.14% | $14.98 | $38.64 +157.94% | $23.60 | -0.30 | 4.25 | +$0.04B+63.70% | Reduced |
| 22 | INVESCO QQQ TRQQQ | 0.04 | 0.81% | 0.14 | $266.28 | $740.39 +178.05% | $266.28 | +0.14 | 0.25 | +$0.07B+178.05% | New |
| 23 | Uber Technologies, Inc.UBER | 0.03 | 0.73% | 1.40 +6.82% | $24.73 | $73.03 +195.31% | $29.05 | +0.09 | 3.50 | +$0.06B+151.42% | Increased |
| 24 | FULL TRUCK ALLIANCE CO LTDYMM | 0.03 | 0.70% | 4.13 +36.34% | $8.00 | - | $16.33 | +1.10 | 1.00 | -$0.03B-51.00% | Increased |
| 25 | KANZHUN LIMITEDBZ | 0.03 | 0.65% | 1.51 +77.62% | $20.37 | - | $23.56 | +0.66 | 0.75 | -$0.00B-13.55% | Increased |
Showing 1-25 of 67
"Holding Period (yrs)" is the latest uninterrupted holding duration, calculated by dividing continuous reported quarters by 4.
Cost basis is an estimate and can differ materially from the actual cost, especially in edge cases.
Cost basis estimate: from the latest uninterrupted holding period, new or increased shares are added to the cost pool at the report price; reductions remove shares at the then-average cost. Example: buy 100 shares at $10 in Q1 and add 50 shares at $16 in Q2, estimated cost basis is (100 x 10 + 50 x 16) / 150 = $12 per share.
Return shows estimated dollar return on top and percentage return below. It uses current price when available, otherwise report price.
Exited Holdings
Stocks no longer disclosed in the current 13F portfolio for 2022 Q4.
| 1 | FORMA THERAPEUTICS HLDGS INCCASS | 1.10 | 2.50 | $40.17 | $19.95 | -$0.02B-50.33% |
| 2 | ACM RESEARCH INC-CLASS AACMR | 0.67 | 2.25 | $24.96 | $12.46 | -$0.01B-50.08% |
| 3 | MP Materials Corp.MP | 0.20 | 0.25 | $27.30 | $27.30 | $0.00B0.00% |
| 4 | VANECK OIL SERVICES ETFOIH | 0.02 | 0.50 | $232.60 | $211.20 | -$0.00B-9.20% |
| 5 | Prelude Therapeutics IncorporatedPRLD | 0.58 | 2.25 | $30.13 | $6.61 | -$0.01B-78.06% |
| 6 | ADC Therapeutics SAADCT | 0.50 | 2.50 | $46.81 | $4.82 | -$0.02B-89.70% |
| 7 | Uxin LimitedUXIN | 1.92 | 3.25 | $2.45 | $0.60 | -$0.00B-75.52% |
Showing 1-7 of 7
Exited holdings are stocks disclosed in the previous report period but no longer disclosed in the current 13F portfolio.
"Holding Period (yrs)" is the latest uninterrupted holding duration, calculated by dividing continuous reported quarters by 4.
Cost basis uses the same weighted cost-pool method as current holdings. Estimated exit price uses the current report period weighted report price when available, otherwise the previous report price; it does not represent the actual sale price.
Exit return shows estimated dollar return on top and percentage return below.
Portfolio Visuals
Track portfolio value, position weights and Top 10 history.